Journal
CLINICAL AND EXPERIMENTAL DERMATOLOGY
Volume 46, Issue 6, Pages 1001-1010Publisher
WILEY
DOI: 10.1111/ced.14625
Keywords
-
Categories
Funding
- British Association of Dermatologists [Undergraduate Project Award] Funding Source: Medline
Ask authors/readers for more resources
Erythroderma, a cutaneous inflammatory state with skin barrier and metabolic dysfunctions, has an estimated annual incidence of 1-2 per 100,000 in Europe with a male preponderance. While associated with a broad range of diseases, the majority of cases result from pre-existing chronic dermatoses.
Erythroderma (exfoliative dermatitis), first described by Von Hebra in 1868, manifests as a cutaneous inflammatory state, with associated skin barrier and metabolic dysfunctions. The annual incidence of erythroderma is estimated to be 1-2 per 100 000 population in Europe with a male preponderance. Erythroderma may present at birth, or may develop acutely or insidiously (due to progression of an underlying primary pathology, including malignancy). Although there is a broad range of diseases that associate with erythroderma, the vast majority of cases result from pre-existing and chronic dermatoses. In the first part of this two-part concise review, we explore the underlying causes, clinical presentation, pathogenesis and investigation of erythroderma, and suggest potential treatment targets for erythroderma with unknown causes.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available